High Drug Prices and Costly Care Raise Ethical Concerns for Neurologists

2021 ◽  
Vol 21 (22) ◽  
pp. 20-21
Author(s):  
Olga Rukovets
Keyword(s):  
High Drug ◽  
Ethical Concerns ◽  
Drug Prices

House investigates high drug prices

2019 ◽  
Vol 76 (8) ◽  
pp. 483-483
Author(s):  
Kate Traynor
Keyword(s):  
High Drug ◽  
Drug Prices

scholarly journals Canada’s high drug prices under review

2016 ◽  
Vol 188 (13) ◽  
pp. E306-E306
Author(s):  
donalee Moulton
Keyword(s):  
High Drug ◽  
Drug Prices

Are high drug prices for hematologic malignancies justified? A critical analysis

Cancer ◽  
2015 ◽  
Vol 121 (19) ◽  
pp. 3372-3379 ◽  
Author(s):  
Jagpreet Chhatwal ◽  
Michael Mathisen ◽  
Hagop Kantarjian
Keyword(s):  
Critical Analysis ◽  
Hematologic Malignancies ◽  
High Drug ◽  
Drug Prices

scholarly journals Drivers of High Drug Prices in Japan, A Preliminary Research

2018 ◽  
Vol 21 ◽  
pp. S9-S10
Author(s):  
M Ueyama ◽  
A Fukushima ◽  
Y Oku ◽  
J Dorey ◽  
Y Onishi ◽  
...  
Keyword(s):  
High Drug ◽  
Drug Prices ◽  
Preliminary Research

Pharmaceuticals, Patents, and Politics: Canada and Bill C-22

1993 ◽  
Vol 23 (1) ◽  
pp. 147-160 ◽  
Author(s):  
Joel Lexchin
Keyword(s):  
United States ◽  
Research And Development ◽  
Patent Protection ◽  
The United States ◽  
New Drugs ◽  
Compulsory Licensing ◽  
High Drug ◽  
Drug Prices ◽  
Future Demands ◽  
The Impact

In response to high drug prices, the Canadian government amended the country's patent act in 1969 to allow for compulsory licensing to import pharmaceuticals. As a result of the legislation, by 1983 drug costs in Canada were over $200 million lower than they would otherwise have been. The multinational drug industry was strongly opposed to compulsory licensing, despite any evidence that its economic position had been harmed. Restoration of patent protection for drugs was one of the key U.S. demands during free-trade negotiations between Canada and the United States in 1985–1987. The result was Bill C-22, which gave new drugs protection from compulsory licensing for seven to ten years. This article analyzes the impact of Bill C-22 on the generic industry, the creation of jobs in research and development, drug prices, and research and development expenditures. It concludes with an examination of future demands from the pharmaceutical industry.

The Gilead Model and the Perspective of Big Pharma

2017 ◽  
Author(s):  
Murphy Halliburton
Keyword(s):  
Pharmaceutical Companies ◽  
Real Problem ◽  
Middle Income ◽  
High Drug ◽  
Poor Countries ◽  
Middle Income Countries ◽  
Drug Prices ◽  
The Poor ◽  
Recommended Therapy ◽  
Hiv Aids

Here this study takes into account the perspective of multinational pharmaceutical companies. I first discuss the difficulties I encountered in getting access to individuals from pharmaceutical companies who would speak on patent issues and how I was eventually able to speak with representatives from Gilead and Pfizer. Gilead Sciences, a mid-size US-based company, is voluntarily allowing 16 Indian generic pharmaceutical producers to manufacture their drug, tenofovir, a crucial WHO-recommended therapy for HIV/AIDS, and as a result, the price of tenofovir has gone down dramatically. This chapter assesses the meaning of these events and argues that the priority of pharmaceutical companies under the new patent regime is not to get people in poor countries to start paying high drug prices but to protect their markets in wealthy and middle-income countries. The real problem of access under the new patent regime may turn out to be for the poor who live in middle-income countries.

Sign in / Sign up

Export Citation Format

Share Document